Vildapin Plus 850


Vildapin Plus 850


Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)



Vildagliptin + Metformin Hydrochloride



Patients with type 2 diabetes mellitus who are not adequately controlled on Metformin Hydrochloride or Vildagliptin alone, or who are already treated with the combination of Vildagliptin and Metformin Hydrochloride as separate tablets, should take this tablet as an adjunct to diet and exercise to improve glycaemic control.



Vildagliptin works by blocking DPP-4 (Dipeptidyl peptidase-4), an enzyme that breaks down the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucagon-like peptide-2) (glucose-dependent insulinotropic polypeptide). Vildagliptin inhibits DPP-4 activity quickly and completely, resulting in higher endogenous levels of the incretin hormones GLP-1 and GIP during fasting and postprandial periods. Vildagliptin enhances insulin secretion from the pancreatic beta cell while decreasing glucagon secretion from the alpha cell by boosting endogenous levels of these incretin hormones.Increased incretin hormone levels cause a rise in the insulin/glucagon ratio during hyperglycemia, which leads to a decrease in fasting and postprandial hepatic glucose production, resulting in lower glycemia.

Metformin Hydrochloride is an antihyperglycemic medication of the biguanide class that is used to treat type 2 diabetes. Both baseline and postprandial plasma glucose levels are reduced. It has a different mode of action than sulfonylureas and does not cause hypoglycemia. By increasing peripheral glucose uptake and utilization, glucomin lowers hepatic glucose synthesis, lowers intestinal glucose absorption, and increases insulin sensitivity.


Dosage & Administration

Adults: Based on the patient’s current dose of Metformin, this combination may be initiated at twice daily, 1 tablet in the morning and the other in the evening. Patients receiving Vildagliptin and Metformin from separate tablets may be switched to this combination containing the same doses of each component. Doses higher than 100 mg of vildagliptin are not recommended. There is no clinical experience of Vildagliptin and Metformin in triple combination with other antidiabetic agents. Taking this combination with or just after food may reduce gastrointestinal symptoms associated with Metformin.



No clinically significant pharmacokinetic interaction was watched when Vildagliptin (100 mg once every day) was co-administered with Metformin Hydrochloride (1,000 mg once every day). Vildagliptin encompasses a low potential for sedate intuitive. Since Vildagliptin isn’t a cytochrome P (CYP) 450 protein substrate nor does it restrain nor actuates CYP 450 proteins, it isn’t likely to associated with co-medications that are substrates, inhibitors or inducers of these proteins. As a result of these considers no clinically significant intelligent with other verbal antidiabetics (glibenclamide, pioglitazone, metformin hydrochloride), amlodipine, digoxin, ramipril, simvastatin, valsartan or warfarin were watched after co-administration with vildagliptin. On the other hand, furosemide, nifedipine and glyburide increment Cmax and blood AUC of Metformin with no alter in renal clearance of Metformin.



This combination is contraindicated in patients with known touchiness to Vildagliptin or Metformin Hydrochloride or to any of the excipients. It is contraindicated in patients with renal malady or renal brokennessintense myocardial localized necrosis, and septicaemia. It is additionally contraindicated in patients with congestive heart disappointment patients and in patients with intense or unremitting metabolic acidosis, counting diabetic ketoacidosis, with or without coma. It ought to be incidentally ceased in patients experiencing radiologic ponders including intravascular organization of iodinated differentiate materials, since utilize of such items may result in intense modification of renal function.


Side Effects

Headache, tremor, dizziness, nausea, hypoglycemia, and other side effects are the most common.


Pregnancy & Lactation

Because there are no good and well-controlled studies in pregnant women, this combination should not be taken during pregnancy unless the possible benefit outweighs the risk to the fetus. There have been no research done on the components of this combination. This combination should not be given to breast-feeding women because it is unknown whether Vildagliptin and/or Metformin Hydrochloride are excreted in human milk.


Precautions & Warnings

Lactic acidosis can happen due to Metformin amassingIn case metabolic acidosis is suspected, treatment ought to be ceased and the quiet ought to be hospitalized quickly. Serum creatinine ought to be checked at slightest once a year in patients with typical renal work and 2–4 times a year in patients with serum creatinine levels at the upper constrain of typical and in elderly patients. Uncommon caution ought to be worked out in elderly patients where renal work may ended up disabled (e.g. when starting antihypertensives, diuretics or NSAIDs). It is suggested that Liver Work Tests (LFTs) are observed earlier to start of this medicate, at three-monthly interims within the to begin with year and occasionally from that pointIn the event that transaminase levels are expanded, patients ought to be checked with a moment liver work assessment to affirm the finding and be taken after from there on with visit liver work tests until the variation from the norm return to ordinaryIn the event that AST or ALT continue at 3 x ULN, Vildaglipt


Therapeutic Class

Combination Oral hypoglycemic preparations


Storage Conditions

Keep in a dry place away from light and heat. Keep out of the reach of children.


Pharmaceutical Name

ACME Laboratories Ltd.